GABARAPL2 Inhibitors
GABARAPL2 inhibitors constitute a diverse group of compounds that modulate the function of Gamma-Aminobutyric Acid Receptor-Associated Protein-Like 2 (GABARAPL2), a key player in autophagy-related processes. Among these inhibitors, autophagy modulators such as Spautin-1, Chloroquine, and Bafilomycin A1 exert their influence by disrupting the autophagic flux, leading to indirect modulation of GABARAPL2. These compounds interfere with autophagy-dependent regulation of GABARAPL2, affecting its activation and subsequent cellular responses associated with GABARAPL2 signaling.
Furthermore, inhibitors like Wortmannin, LY294002, and Rapamycin act indirectly by targeting the phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway. By inhibiting PI3K or mTOR, these compounds disrupt downstream signaling cascades involving GABARAPL2, influencing its function indirectly. Another group of inhibitors, including PF-4708671, SB203580, and U0126, modulates GABARAPL2 through diverse signaling pathways such as AMP-activated protein kinase (AMPK), p38 mitogen-activated protein kinase (MAPK), and mitogen-activated protein kinase kinase (MEK), respectively. These inhibitors interfere with the corresponding signaling pathways, affecting GABARAPL2 activation and the subsequent cellular responses influenced by GABARAPL2 signaling. In conclusion, GABARAPL2 inhibitors provide a spectrum of options for modulating GABARAPL2 function, either directly or indirectly, through their impact on autophagy or diverse signaling pathways. Understanding the specific mechanisms by which these inhibitors interact with GABARAPL2 opens avenues for precise control of GABARAPL2-mediated cellular processes in various contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $168.00 | ||
Spautin-1 is an inhibitor of autophagy that indirectly modulates GABARAPL2. By inhibiting autophagy, Spautin-1 disrupts the cellular processes involving GABARAPL2, leading to its indirect modulation. This indirect inhibition occurs through interference with autophagy-dependent regulation of GABARAPL2, affecting its activation and the subsequent cellular responses influenced by GABARAPL2 signaling. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine is an autophagy inhibitor that indirectly modulates GABARAPL2. By inhibiting autophagy, Chloroquine disrupts the cellular processes involving GABARAPL2, leading to its indirect modulation. This indirect inhibition occurs through interference with autophagy-dependent regulation of GABARAPL2, affecting its activation and the subsequent cellular responses influenced by GABARAPL2 signaling. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is an inhibitor of autophagy that indirectly modulates GABARAPL2. By inhibiting autophagy, Bafilomycin A1 disrupts the cellular processes involving GABARAPL2, leading to its indirect modulation. This indirect inhibition occurs through interference with autophagy-dependent regulation of GABARAPL2, affecting its activation and the subsequent cellular responses influenced by GABARAPL2 signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a phosphoinositide 3-kinase (PI3K) inhibitor that indirectly modulates GABARAPL2 through the PI3K/Akt/mTOR pathway. By inhibiting PI3K, Wortmannin disrupts downstream signaling cascades involving GABARAPL2, indirectly influencing its function. This indirect modulation occurs through the interference with the PI3K-dependent regulation of GABARAPL2, affecting its activation and the subsequent cellular responses influenced by GABARAPL2 signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase (PI3K) inhibitor that indirectly modulates GABARAPL2 through the PI3K/Akt/mTOR pathway. By inhibiting PI3K, LY294002 disrupts downstream signaling cascades involving GABARAPL2, indirectly influencing its function. This indirect modulation occurs through the interference with the PI3K-dependent regulation of GABARAPL2, affecting its activation and the subsequent cellular responses influenced by GABARAPL2 signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that indirectly modulates GABARAPL2 through the mTOR signaling pathway. By inhibiting mTOR, Rapamycin disrupts downstream signaling cascades involving GABARAPL2, indirectly influencing its function. This indirect modulation occurs through the interference with the mTOR-dependent regulation of GABARAPL2, affecting its activation and the subsequent cellular responses influenced by GABARAPL2 signaling. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
3-Methyladenine is an inhibitor of autophagy that indirectly modulates GABARAPL2. By inhibiting autophagy, 3-Methyladenine disrupts the cellular processes involving GABARAPL2, leading to its indirect modulation. This indirect inhibition occurs through interference with autophagy-dependent regulation of GABARAPL2, affecting its activation and the subsequent cellular responses influenced by GABARAPL2 signaling. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $179.00 $700.00 | 9 | |
PF-4708671 is an AMP-activated protein kinase (AMPK) inhibitor that indirectly modulates GABARAPL2 through the AMPK/mTOR pathway. By inhibiting AMPK, PF-4708671 disrupts downstream signaling cascades involving GABARAPL2, indirectly influencing its function. This indirect modulation occurs through the interference with the AMPK-dependent regulation of GABARAPL2, affecting its activation and the subsequent cellular responses influenced by GABARAPL2 signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 mitogen-activated protein kinase (MAPK) inhibitor that indirectly modulates GABARAPL2 through the p38 MAPK pathway. By inhibiting p38 MAPK, SB203580 disrupts downstream signaling cascades involving GABARAPL2, indirectly influencing its function. This indirect modulation occurs through the interference with the p38 MAPK-dependent regulation of GABARAPL2, affecting its activation and the subsequent cellular responses influenced by GABARAPL2 signaling. | ||||||
LY 303511 | 154447-38-8 | sc-202215 sc-202215A | 1 mg 5 mg | $67.00 $278.00 | 3 | |
LY303511 is a phosphoinositide 3-kinase (PI3K) inhibitor that indirectly modulates GABARAPL2 through the PI3K/Akt/mTOR pathway. By inhibiting PI3K, LY303511 disrupts downstream signaling cascades involving GABARAPL2, indirectly influencing its function. This indirect modulation occurs through the interference with the PI3K-dependent regulation of GABARAPL2, affecting its activation and the subsequent cellular responses influenced by GABARAPL2 signaling. | ||||||